search
Back to results

A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL

Primary Purpose

Relapsed Chronic Lymphocytic Leukemia

Status
Active
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Metformin
Sponsored by
University of Michigan Rogel Cancer Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Relapsed Chronic Lymphocytic Leukemia focused on measuring Relapsed Chronic Lymphocytic Leukemia, untreated CLL patients, genomic deletion 11q

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patients should have a confirmed diagnosis of chronic lymphocytic leukemia defined as all of the following:

    • ALC > 5000
    • Positive for either CD19 or CD 20 together with CD23 and CD5.
    • Less than 55% atypical cells
  2. Patients who relapse after receiving a one or more courses of fludarabine, bendamustine, cytoxan, rituxan, chlorambucil, or campath based therapy.

  3. Patients should have findings of relapse by one or both of the following:

    • ALC > 5000 on 2 consecutive occasions and increasing
    • Any increase in lymphadenopathy over best response that has persisted for more than 3 months
  4. Patient with confirmed del11q mutation may be included if untreated.
  5. Age > or equal to 18 years old and < 80 years of age during the course of therapy
  6. ECOG performance 0-2
  7. Life expectancy > 12 months

  8. Patients must have normal organ function as defined as below:

    • AST and ALT < 2 times the upper limit of normal
    • alkaline phosphatase < 2 ULN
    • serum conjugated bilirubin < 1.5 ULN (exception of Gilbert disease)
    • serum creatinine less than or equal to 1.5 in males, or 1.4 in females
    • GFR > 59
  9. Ability to understand and the willingness to sign a written informed consent document
  10. Patient must be able to drink and eat more than 75% of their usual daily meals.

Exclusion Criteria:

  1. Patients with active CLL disease requiring urgent chemotherapy
  2. Patients may not be receiving any other investigational agents.
  3. Patients less than 30 days from last treatment for CLL.
  4. History of allergic reactions attributed to metformin or other biguanides.
  5. Known diabetes (type 1 or 2), fasting glucose > or equal to 7.0 mmol/L (126 mg/dL), or HgbA1C > 6.5
  6. Currently taking metformin, sulfonylureas, thiazolidinediones or insulin for any reason
  7. Current or planned pregnancy or lactation in women of child bearing age (confirmed by negative pregnancy test prior to start of therapy).
  8. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection and sepsis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

  9. Conditions which would increase risk of lactic acidosis including:

    • Known alcoholism or ingestion of more than 3 alcoholic beverages per day
    • History of congestive heart failure defined as NYHA class III or IV
    • History of metabolic acidosis
    • Ongoing or active infection concerning for sepsis or SIRS

Sites / Locations

  • University of Michigan Comprehensive Cancer Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Metformin (Glucophage)

Arm Description

The starting dose of metformin will be 500 mg po daily for one week. The dose can be escalated to 500 mg twice a day after one week, and further escalated to the final dose of 1000 mg twice a day in week 3 if the medication is tolerated without adverse side effects (refer to holding parameters described in section 9.3.3). All doses should be administered with food to decrease gastrointestinal upset.

Outcomes

Primary Outcome Measures

Time to treatment failure
While patients are on metformin therapy, time to treatment failure will be defined as one or all of the following criteria: ALC > 5000 on 3 occasions after start of metformin treatment and increasing by 25% or more on each occasion, which will be measured every 3 months. An increase of Rai Stage (0-3) by one stage. An increase in any lymph node by >50% as assessed by either physical exam (all patients) or CT scanning (only if ordered as part of routine clinical management). Worsening cytopenias (Hemoglobin <11 g/dl) associated with a bone marrow biopsy result indicating advanced stage CLL (packed CLL marrow).

Secondary Outcome Measures

Time to first therapy (TTFT) in previously untreated 11q CLL subsets only.
To evaluate TTFT in untreated patients, the product-limit method of Kaplan and Meier will be used similarly to the primary endpoint. The main difference between this endpoint and the primary endpoint is that TTFT will be defined from the date of CLL diagnosis for untreated delq11 patients
Changes in the rate of increase of absolute lymphocyte count while on metformin therapy
Longitudinal lymphocyte counts will be modeled using mixed models methodology, whereby both fixed effects (dose of metformin) and random effects (intercept - starting lymphocyte count) can be modeled.
Change in size of clinically appreciated lymphadenopathy in cm and splenomegaly while on metformin therapy
The proportion of patients that begin metformin therapy with these conditions will be summarized, along with the proportions at study defined clinical assessment points during therapy. No statistical models will be employed, but proportions and 95% exact binomial confidence intervals will be reported for descriptive purposes.
Change in number of clinically appreciated lymphadenopathy and splenomegaly while on metformin therapy
The proportion of patients that begin metformin therapy with these conditions will be summarized, along with the proportions at study defined clinical assessment points during therapy. No statistical models will be employed, but proportions and 95% exact binomial confidence intervals will be reported for descriptive purposes.

Full Information

First Posted
October 2, 2012
Last Updated
August 30, 2023
Sponsor
University of Michigan Rogel Cancer Center
search

1. Study Identification

Unique Protocol Identification Number
NCT01750567
Brief Title
A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL
Official Title
A Phase II Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia and Untreated CLL Patients With Genomic Deletion 11q
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
November 2012 (Actual)
Primary Completion Date
May 2024 (Anticipated)
Study Completion Date
May 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Michigan Rogel Cancer Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Metformin is an antidiabetic drug which is an inexpensive and generally well tolerated medication. More recently metformin has been shown to act against carcinomas by two mechanisms: 1) an indirect, insulin-dependent mechanism which sensitizes tissues to insulin, inhibits hepatic gluconeogenesis, and stimulates uptake of glucose in muscle, thereby reducing fasting blood glucose and circulating levels of insulin, lowering the pro survival activity of the insulin/INSR axis, and 2) a direct, insulin-independent mechanism which activates the AMP-activated protein kinase (AMPK) pathway and leads to inhibition of the mTOR pathway. Given the investigators preliminary published data on insulin and mTOR inhibition[1] metformin is an attractive candidate for a pilot clinical trial in CLL patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Relapsed Chronic Lymphocytic Leukemia
Keywords
Relapsed Chronic Lymphocytic Leukemia, untreated CLL patients, genomic deletion 11q

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
37 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Metformin (Glucophage)
Arm Type
Experimental
Arm Description
The starting dose of metformin will be 500 mg po daily for one week. The dose can be escalated to 500 mg twice a day after one week, and further escalated to the final dose of 1000 mg twice a day in week 3 if the medication is tolerated without adverse side effects (refer to holding parameters described in section 9.3.3). All doses should be administered with food to decrease gastrointestinal upset.
Intervention Type
Drug
Intervention Name(s)
Metformin
Other Intervention Name(s)
Glucophage
Intervention Description
Metformin is an antidiabetic drug which is an inexpensive and generally well tolerated medication.
Primary Outcome Measure Information:
Title
Time to treatment failure
Description
While patients are on metformin therapy, time to treatment failure will be defined as one or all of the following criteria: ALC > 5000 on 3 occasions after start of metformin treatment and increasing by 25% or more on each occasion, which will be measured every 3 months. An increase of Rai Stage (0-3) by one stage. An increase in any lymph node by >50% as assessed by either physical exam (all patients) or CT scanning (only if ordered as part of routine clinical management). Worsening cytopenias (Hemoglobin <11 g/dl) associated with a bone marrow biopsy result indicating advanced stage CLL (packed CLL marrow).
Time Frame
Until the patient meets failure criteria and stops Metformin; up to 6 months after start of metformin therapy and yearly thereafter.
Secondary Outcome Measure Information:
Title
Time to first therapy (TTFT) in previously untreated 11q CLL subsets only.
Description
To evaluate TTFT in untreated patients, the product-limit method of Kaplan and Meier will be used similarly to the primary endpoint. The main difference between this endpoint and the primary endpoint is that TTFT will be defined from the date of CLL diagnosis for untreated delq11 patients
Time Frame
from time of diagnosis to time of first treatment with anti-neoplastic chemotherapy.
Title
Changes in the rate of increase of absolute lymphocyte count while on metformin therapy
Description
Longitudinal lymphocyte counts will be modeled using mixed models methodology, whereby both fixed effects (dose of metformin) and random effects (intercept - starting lymphocyte count) can be modeled.
Time Frame
Until the patient meets failure criteria and stops Metformin
Title
Change in size of clinically appreciated lymphadenopathy in cm and splenomegaly while on metformin therapy
Description
The proportion of patients that begin metformin therapy with these conditions will be summarized, along with the proportions at study defined clinical assessment points during therapy. No statistical models will be employed, but proportions and 95% exact binomial confidence intervals will be reported for descriptive purposes.
Time Frame
Baseline up to 3 months after completing metformin therapy
Title
Change in number of clinically appreciated lymphadenopathy and splenomegaly while on metformin therapy
Description
The proportion of patients that begin metformin therapy with these conditions will be summarized, along with the proportions at study defined clinical assessment points during therapy. No statistical models will be employed, but proportions and 95% exact binomial confidence intervals will be reported for descriptive purposes.
Time Frame
Baseline up to 3 months after completing metformin therapy

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients should have a confirmed diagnosis of chronic lymphocytic leukemia defined as all of the following: ALC > 5000 Positive for either CD19 or CD 20 together with CD23 and CD5. Less than 55% atypical cells Patients who relapse after receiving a one or more courses of fludarabine, bendamustine, cytoxan, rituxan, chlorambucil, or campath based therapy. Patients should have findings of relapse by one or both of the following: ALC > 5000 on 2 consecutive occasions and increasing Any increase in lymphadenopathy over best response that has persisted for more than 3 months Patient with confirmed del11q mutation may be included if untreated. Age > or equal to 18 years old and < 80 years of age during the course of therapy ECOG performance 0-2 Life expectancy > 12 months Patients must have normal organ function as defined as below: AST and ALT < 2 times the upper limit of normal alkaline phosphatase < 2 ULN serum conjugated bilirubin < 1.5 ULN (exception of Gilbert disease) serum creatinine less than or equal to 1.5 in males, or 1.4 in females GFR > 59 Ability to understand and the willingness to sign a written informed consent document Patient must be able to drink and eat more than 75% of their usual daily meals. Exclusion Criteria: Patients with active CLL disease requiring urgent chemotherapy Patients may not be receiving any other investigational agents. Patients less than 30 days from last treatment for CLL. History of allergic reactions attributed to metformin or other biguanides. Known diabetes (type 1 or 2), fasting glucose > or equal to 7.0 mmol/L (126 mg/dL), or HgbA1C > 6.5 Currently taking metformin, sulfonylureas, thiazolidinediones or insulin for any reason Current or planned pregnancy or lactation in women of child bearing age (confirmed by negative pregnancy test prior to start of therapy). Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection and sepsis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements Conditions which would increase risk of lactic acidosis including: Known alcoholism or ingestion of more than 3 alcoholic beverages per day History of congestive heart failure defined as NYHA class III or IV History of metabolic acidosis Ongoing or active infection concerning for sepsis or SIRS
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sami Malek, MD
Organizational Affiliation
University of Michigan Rogel Cancer Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Michigan Comprehensive Cancer Center
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States

12. IPD Sharing Statement

Learn more about this trial

A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL

We'll reach out to this number within 24 hrs